171 related articles for article (PubMed ID: 18456197)
1. Pharmacotherapy for atrial arrhythmias: present and future.
Mazzini MJ; Monahan KM
Heart Rhythm; 2008 Jun; 5(6 Suppl):S26-31. PubMed ID: 18456197
[TBL] [Abstract][Full Text] [Related]
2. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.
Shiroshita-Takeshita A; Sakabe M; Haugan K; Hennan JK; Nattel S
Circulation; 2007 Jan; 115(3):310-8. PubMed ID: 17224477
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the pharmacological treatment of cardiac arrythmias.
Gramley F; Himmrich E; Mollnau H; Theis C; Hammwohner M; Goette A
Drugs Today (Barc); 2009 Nov; 45(11):807-24. PubMed ID: 20126673
[TBL] [Abstract][Full Text] [Related]
4. Dronedarone: a promising alternative for the management of atrial fibrillation.
Yalta K; Turgut OO; Yilmaz MB; Yilmaz A; Tandogan I
Cardiovasc Drugs Ther; 2009 Oct; 23(5):385-93. PubMed ID: 19669399
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of atrial fibrillation: a pathophysiological perspective and review.
Jacob S; Ali OA; Pidlaoan V; Badheka AO; Kerin NZ
Am J Ther; 2011 May; 18(3):241-60. PubMed ID: 20861719
[TBL] [Abstract][Full Text] [Related]
6. Dronedarone: an emerging therapy for atrial fibrillation.
Rosei EA; Salvetti M
Ther Adv Cardiovasc Dis; 2010 Jun; 4(3):155-64. PubMed ID: 20418270
[TBL] [Abstract][Full Text] [Related]
7. Drug therapy for termination of atrial fibrillation and maintenance of sinus rhythm.
Talajic M; Roy D
Can J Cardiol; 2005 Sep; 21 Suppl B():19B-25B. PubMed ID: 16239983
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives in the pharmacological treatment of atrial fibrillation and ventricular arrhythmias in heart failure.
Baczko I; Leprán I; Kiss L; Muntean DM; Light PE
Curr Pharm Des; 2015; 21(8):1011-29. PubMed ID: 25354185
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic management of atrial fibrillation: established and emerging options.
Kalus JS
J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S10-8. PubMed ID: 19678722
[TBL] [Abstract][Full Text] [Related]
10. New directions in antiarrhythmic drug therapy for atrial fibrillation.
Heijman J; Voigt N; Dobrev D
Future Cardiol; 2013 Jan; 9(1):71-88. PubMed ID: 23259476
[TBL] [Abstract][Full Text] [Related]
11. The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy.
Aguilar M; Nattel S
J Cardiovasc Pharmacol; 2015 Nov; 66(5):432-40. PubMed ID: 25923324
[TBL] [Abstract][Full Text] [Related]
12. Atrial fibrillation: mechanisms, therapeutics, and future directions.
Pellman J; Sheikh F
Compr Physiol; 2015 Apr; 5(2):649-65. PubMed ID: 25880508
[TBL] [Abstract][Full Text] [Related]
13. Dronedarone: an overview.
Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
Ann Med; 2012 Feb; 44(1):60-72. PubMed ID: 21745093
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications.
Fragakis N; Koskinas KC; Vassilikos V
Pacing Clin Electrophysiol; 2014 Oct; 37(10):1412-20. PubMed ID: 25138058
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.
Rosa GM; Bianco D; Parodi A; Valbusa A; Zawaideh C; Bizzarri N; Ferrero S; Brunelli C
Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1751-64. PubMed ID: 25349898
[TBL] [Abstract][Full Text] [Related]
16. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Reiffel JA; Camm AJ; Belardinelli L; Zeng D; Karwatowska-Prokopczuk E; Olmsted A; Zareba W; Rosero S; Kowey P;
Circ Arrhythm Electrophysiol; 2015 Oct; 8(5):1048-56. PubMed ID: 26226999
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.
Kjølbye AL; Haugan K; Hennan JK; Petersen JS
Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):215-30. PubMed ID: 17845503
[TBL] [Abstract][Full Text] [Related]
18. Treatment of atrial fibrillation.
Bajpai A; Savelieva I; Camm AJ
Br Med Bull; 2008; 88(1):75-94. PubMed ID: 19059992
[TBL] [Abstract][Full Text] [Related]
19. Dronedarone: an emerging agent with rhythm- and rate-controlling effects.
Wegener FT; Ehrlich JR; Hohnloser SH
J Cardiovasc Electrophysiol; 2006 Sep; 17 Suppl 2():S17-20. PubMed ID: 16939434
[TBL] [Abstract][Full Text] [Related]
20. Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Duray GZ; Schmitt J; Hohnloser SH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):19S-23S. PubMed ID: 20472812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
